Biogen Pharmachem Industries chairman and AGM
Share price at the BSE close on 28 Oct 2026. Previous close ₹0.24.
28 Oct: open ₹0.25, high ₹0.25, low ₹0.24
- Next results date: the board meets on 3 Nov 2026 to consider: quarterly results. Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹26 Cr3,446th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.27
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −0.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 25,00,278
Biogen Pharmachem Industries' chairperson is KELASH BUNKAR, as filed for the quarter to Sep 2026. Its latest annual general meeting was on 29 Sep 2026.
Biogen Pharmachem Industries board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- ChairpersonKELASH BUNKAR
6 directors5 independent1 non-executive
- CHANDRAKANT GOVINDBHAI PARMARIndependent · joined Nov 2021 · reappointed Sep 2022 · 58 months as independent · 1 listed board · 1 as independent · 2 committee seats
- HARSHADKUMAR RATHODIndependent · joined Mar 2023 · reappointed Sep 2023 · 45 months as independent · 3 listed boards · 2 as independent
- NARENDRAKUMAR VANIYAIndependent · joined Mar 2023 · reappointed Sep 2023 · 45 months as independent · 3 listed boards · 3 as independent · 1 committee seat, 3 as chair
- CHHAYABEN MAHESHBHAI PARMARIndependent · joined Jan 2024 · reappointed Jan 2024 · 33 months as independent · 3 listed boards · 3 as independent · 2 committee seats, 4 as chair
- KELASH BUNKAR · ChairpersonNon-executive · joined Feb 2025 · reappointed Sep 2025 · 3 listed boards · 2 as independent · 4 committee seats, 2 as chair
- AMAN PRAVINKUMAR PATELIndependent · joined Feb 2025 · reappointed Sep 2025 · 20 months as independent · 3 listed boards · 2 as independent
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
2 directors who left
- NIRAJ VAGHELA, left 5 Feb 2025: Others
- KOMALBEN CHAUHAN, left 5 Feb 2025: Others
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 5 Aug 20266 of 6 present5 independent · 82 days in between
- 14 May 20266 of 6 present5 independent
Audit Committee
Chair CHHAYABEN MAHESHBHAI PARMAR
CHANDRAKANT GOVINDBHAI PARMAR, KELASH BUNKAR
- 5 Aug 20263 of 3 present2 independent · 82 days in between
- 14 May 20263 of 3 present2 independent
Nomination and remuneration committee
Chair CHANDRAKANT GOVINDBHAI PARMAR
CHHAYABEN MAHESHBHAI PARMAR, KELASH BUNKAR
No meeting listed in the filing.
Stakeholders Relationship Committee
Chair CHHAYABEN MAHESHBHAI PARMAR
CHANDRAKANT GOVINDBHAI PARMAR, KELASH BUNKAR
No meeting listed in the filing.
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- Goenka Mehta & Associates Chartered AccountantsPeer-review certificate valid to Nov 2027
1 earlier auditor
- RISHI SEKHRI AND ASSOCIATES Chartered AccountantsNamed in the filing for the quarter to Mar 2025
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Biogen Pharmachem Industries AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.
Annual general meeting, 29 Sep 2026
3,00,794 shareholders on the register on 22 Sep 2026; present: 0 promoters and 32 others; votes counted by DAKSHA NEGI / DAKSHA NEGI & ASSOCIATES.The company's voting result
- Ordinary Resolution for adoption of the audited financial statements of the Company for the Financial Year ended 31st March 2026 and Reports of the Directors and Auditors thereon.Ordinary99.98% for0.02% against
Against: promoters 0.00% · institutions 0.00% · other public 0.02%
Turnout: all 5.25% · promoters 0.00% · institutions 0.00% · other public 5.25%
- Ordinary Resolution for re-appointment of Mr. Kelash Bunkar (DIN: 10911360), as director of the Company who retires by rotation.Ordinary99.64% for0.36% against
Against: promoters 0.00% · institutions 0.00% · other public 0.36%
Turnout: all 5.25% · promoters 0.00% · institutions 0.00% · other public 5.25%
- Ordinary Resolution for appointment of M/s. Goenka Mehta & Associates Chartered Accountants, Rajkot (Firm Registration No: 129445W) as Statutory auditors and fix their remuneration.Ordinary99.93% for0.07% against
Against: promoters 0.00% · institutions 0.00% · other public 0.07%
Turnout: all 5.25% · promoters 0.00% · institutions 0.00% · other public 5.25%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Jun 2025. The company's results filing for the quarter to Jun 2026 says no statement of how money raised was used applies to it. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Preferential IssuesApr 2025 | 25.00 | Preferential Issue | 25.00 | 25.00 | No |